JP2017515901A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515901A5
JP2017515901A5 JP2017511565A JP2017511565A JP2017515901A5 JP 2017515901 A5 JP2017515901 A5 JP 2017515901A5 JP 2017511565 A JP2017511565 A JP 2017511565A JP 2017511565 A JP2017511565 A JP 2017511565A JP 2017515901 A5 JP2017515901 A5 JP 2017515901A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
aryl
heteroaryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017511565A
Other languages
English (en)
Japanese (ja)
Other versions
JP6419313B2 (ja
JP2017515901A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030014 external-priority patent/WO2015172099A1/en
Publication of JP2017515901A publication Critical patent/JP2017515901A/ja
Publication of JP2017515901A5 publication Critical patent/JP2017515901A5/ja
Application granted granted Critical
Publication of JP6419313B2 publication Critical patent/JP6419313B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017511565A 2014-05-09 2015-05-08 抗ウイルスの化合物、医薬組成物およびその使用方法 Expired - Fee Related JP6419313B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461991418P 2014-05-09 2014-05-09
US61/991,418 2014-05-09
US201562177900P 2015-03-25 2015-03-25
US62/177,900 2015-03-25
PCT/US2015/030014 WO2015172099A1 (en) 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2017515901A JP2017515901A (ja) 2017-06-15
JP2017515901A5 true JP2017515901A5 (enExample) 2018-04-05
JP6419313B2 JP6419313B2 (ja) 2018-11-07

Family

ID=54393071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511565A Expired - Fee Related JP6419313B2 (ja) 2014-05-09 2015-05-08 抗ウイルスの化合物、医薬組成物およびその使用方法

Country Status (9)

Country Link
US (3) US9884876B2 (enExample)
EP (1) EP3139920A4 (enExample)
JP (1) JP6419313B2 (enExample)
CN (1) CN106456615B (enExample)
AU (3) AU2015255714B2 (enExample)
CA (1) CA2948178A1 (enExample)
MX (2) MX2016014642A (enExample)
TW (1) TW201623265A (enExample)
WO (1) WO2015172099A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
CA3051422A1 (en) * 2018-08-09 2020-02-09 Kineta, Inc. Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof
TW202035426A (zh) * 2018-08-17 2020-10-01 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
US20220009945A1 (en) * 2018-11-02 2022-01-13 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv)
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
US20220273689A1 (en) * 2019-07-09 2022-09-01 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
JP2022550454A (ja) * 2019-10-02 2022-12-01 ユニバーシティ オブ ワシントン B型肝炎ウイルス感染の治療のための組成物及び方法
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
BR112022020020A2 (pt) 2020-04-04 2022-11-22 Pfizer Métodos de tratamento da doença do coronavírus 2019
MX2021013934A (es) 2020-04-05 2021-12-15 Pfizer Compuestos y metodos para el tratamiento de covid-19.
US12485157B2 (en) 2020-04-05 2025-12-02 Pfizer Inc. Method of treating COVID-19
US12358897B2 (en) 2020-04-05 2025-07-15 Pfizer Inc. Compounds and method of treating COVID-19
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CN113831301B (zh) * 2020-06-08 2023-06-06 沈阳药科大学 苯并噻唑类衍生物及其用途
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
EP4228631B1 (en) * 2020-10-15 2024-08-21 Baden-Württemberg Stiftung gGmbH Flavi-block: a pan-flavivirus inhibitor
WO2022180003A1 (en) * 2021-02-24 2022-09-01 F. Hoffmann-La Roche Ag Benzothiazolyl bicyclo[1.1.1]pentane derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2022204431A1 (en) * 2021-03-24 2022-09-29 Anavex Life Sciences Corp. Prevention and treatment of coronavirus infection
US20250304559A1 (en) 2021-03-30 2025-10-02 Pfizer Inc. Ether-Linked Antiviral Compounds
TWI869780B (zh) 2022-03-02 2025-01-11 美商輝瑞大藥廠 用於篩檢人類個體之呼吸疾病、監測人類個體之呼吸病況以及提供決策支援之方法及電腦化系統
WO2024149990A1 (en) 2023-01-10 2024-07-18 Oxford University Innovation Limited Nirmatrelvir analogs as 3c like protease inhibitors for treating viral infections
CN121311467A (zh) 2023-06-09 2026-01-09 辉瑞大药厂 N-(甲氧羰基)-3-甲基-l-缬氨酰基-(4r)-n-{(1s)-1-氰基-2-[(3s)-2-氧代吡咯烷-3-基]乙基}-4-(三氟甲基)-l-脯氨酰胺及其溶剂化物的固体形式
WO2025037206A1 (en) 2023-08-11 2025-02-20 Pfizer Inc. Deuterated antiviral compounds
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2025191272A1 (en) 2024-03-13 2025-09-18 Storm Therapeutics Ltd Inhibitory compounds
CN119707862B (zh) * 2025-02-24 2025-06-27 北京悦康科创医药科技股份有限公司 基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024316A (en) * 1911-07-29 1912-04-23 Singer Mfg Co Strip folding and guiding attachment for sewing-machines.
JPS53129036A (en) * 1977-04-18 1978-11-10 Fuji Photo Film Co Ltd Color photographic material
JPH0780355B2 (ja) * 1987-01-22 1995-08-30 富士写真フイルム株式会社 光学的情報記録媒体
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2004078115A2 (en) * 2003-02-28 2004-09-16 Viropharma, Incorporated Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases
US20050130974A1 (en) * 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
CN101925300A (zh) * 2007-11-21 2010-12-22 雅培制药有限公司 作为大麻素受体配体的新化合物和其用途
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2012155352A1 (en) * 2011-05-19 2012-11-22 Eli Lilly And Company Dihydroisoxazole compounds, parasiticidal uses and formulations thereof
AU2012315953A1 (en) * 2011-09-30 2014-04-03 Kineta, Inc. Anti-viral compounds
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
CN103193770B (zh) * 2013-03-20 2015-10-28 中国人民解放军第二军医大学 取代苯并噻唑类抗真菌化合物及其制备方法与应用

Similar Documents

Publication Publication Date Title
JP2013518107A5 (enExample)
JP2013032389A5 (enExample)
PH12018550201A1 (en) Hepatitis b antiviral agents
JP2014521688A5 (enExample)
EP3954679A3 (en) Amide compounds for the treatment of hiv infections
BR112015014457A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
JP2017537066A5 (enExample)
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
JP2016515561A5 (enExample)
TR201906470T4 (tr) İmmünomodülatörler.
NZ729150A (en) Antiretroviral agents
JP2012144574A5 (enExample)
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
PH12013500015A1 (en) 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
JP2016540742A5 (enExample)
JOP20210249A1 (ar) مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbv
GEP20156263B (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for production and usage thereof
EA200901241A1 (ru) Соединения для лечения гепатита с
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
JP2016540749A5 (enExample)
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
ECSP13012438A (es) Proceso para preparar compuestos antivirales
JP2012518649A5 (enExample)